Three years ago, 23andMe was thriving with a share price higher than Apple's, but now it's struggling to survive, raising concerns over its massive DNA database.
The rapid decline from a peak share price of $321 to under $5 is attributed to a lack of a sustainable business model post-DNA report and slow progress in drug research.
Professor Dimitris Andriosopoulos notes that 23andMe's model faltered because customers had little incentive to return after their initial DNA report.
Despite its challenges, 23andMe insists on its commitment to customer data protection, even as it faces tough questions about its future.
Collection
[
|
...
]